# Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

> **NCT03237481** · PHASE3 · COMPLETED · sponsor: **Heron Therapeutics** · enrollment: 418 (actual)

## Conditions studied

- Postoperative Pain

## Interventions

- **DRUG:** HTX-011
- **DRUG:** Bupivacaine HCl
- **DRUG:** Saline placebo
- **DEVICE:** Luer-lock applicator
- **DEVICE:** Vial access device

## Key facts

- **NCT ID:** NCT03237481
- **Lead sponsor:** Heron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2017-12-22
- **Final completion:** 2018-01-16
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237481, "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)". Retrieved via AI Analytics 2026-05-16 from https://api.ai-analytics.org/clinical/NCT03237481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*